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1 
MICROCYSTINS AS AGENTS FOR 
TREATMENT OF CANCER 
CONTINUING APPLICATION DATA 
2 
SUMMARY OF THE INVENTION 
The present invention provides new methods for treating 
cancers, including treating tumors and/or metastatic disease 
This application claims benefit of U.S. Provisional Appli-
cation No. 60/799,013, filed May 10, 2006, which is incor-
porated by reference herein in its entirety. 
5 and/or inhibiting the growth of tumors. The methods and 
combination therapies are preferably directed towards the 
treatment of OAT1B1- and/or OAT1B3-expressing cancers 
such as lung cancers, breast cancer, colon cancer, hepatocel-
lular carcinoma and other tumors. 
FIELD OF THE INVENTION 10 Accordingly, one aspect of the invention provides a method 
for treating cancer comprising administering to a subject in 
need thereof a pharmaceutically effective amount of a micro-
cystin. Non-limiting examples of cancers to be treated are 
hepatocellular cancer, gastrointestinal cancer, lung cancer, 
This invention relates to the use of microcystins as agents 
for treatment of cancer. Also provided are methods of screen-
ing for microcystins with improved cytotoxicity. 
BACKGROUND 
Phosphorylation of intracellular proteins is a key mecha-
nism in the regulation of signal transduction. Kinases, 
enzymes that catalyze protein phosphorylation, are mediators 
15 gastric cancer, colon cancer, pancreatic cancer, gall bladder 
cancer, breast cancer, glioblastoma, and metastatic cancers 
and intraperitoneal disseminations thereof. The cancer is 
preferably hepatocellular cancer, gastrointestinal cancer, or 
non-small cell lung cancer. The microcystin can be a hep-
20 tapeptide with the basic structure cyclo (D-Ala-X-erythro-~­
methyl-D-iso-Asp-Y-Adda-D-iso-Glu-N -methyldehydro-
Ala ), where X andY represent variable amino acids, andAdda 
is the ~-amino acid, 3-amino-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid. Preferably, X andY are L amino 
of the signal cascades, which activate multiple pathways 
involving the governance of cell division and cell death. Phos-
phatases are enzymes that counter the activity ofkinases and 
remove organic phosphates from their active sites on regula-
tory molecules, which generally cause cessation of the acti-
vation signals. The importance of protein phosphatases in cell 
biology is underscored by the estimation that these proteins 
constitute greater than 1% of all of the proteins encoded in the 
human genome (1). Mammalian protein phosphatases have 30 
been placed into five subfamilies, designated PP1, PP2A, 
PP2B, PP5 and PP7 [reviewed in (2)]. 
25 acids. More preferably, X is leucine andY is either arginine, 
phenylalanine, or tryptophan. 
Microcystins are inhibitors ofPP1 and PP2A and are gen-
erally known as hepatotoxins that result from cyanobacterial 
contamination of water supplies. Structurally, microcystins 35 
are cyclic heptapeptides with the basic structure cyclo (D-Ala 
L-X-erythro-b-methyl-D-iso-ASP-L-Y-adda-D-iso-Glu-N-
methyldehydro-Ala) where L-X and L-Y represent variable 
L-amina acids, and Adda is the b-amino acid 3-amino-9-
methoxy-2, 6, 8-trimethyl-1 0-pheny ldeca -4, 6-dienoic acid 40 
(3). The most commonly studied microcystin is microcystin 
LR (FIG. 6), in which the two variable amino acids are leucine 
and arginine. The structures of at least 50 microcystin variants 
have been determined ( 4) differing almost exclusively in the 
two variable residues, which can be other L-amina acids in 45 
substitution for leucine and arginine. The variable nature of 
these compounds suggests that they may have a spectrum of 
biological effects and that there are opportunities for combi-
natorial engineering of therapeutic microcystin compounds. 
The specific hepatic toxicity of microcystins results from 50 
the restricted hepatic expression of the organic anion trans-
porters OATP1B1, OATP1B3 andOATP1A2, which mediate 
the cellular uptake of microcystins. OATP 1 B 1 and OATP 1 B3 
transporters have previously been known as Liver Specific 
Transporters 1 and 2 (LSTl and LST2), respectively, in rec- 55 
ognition of gene expression limited to the liver. The potential 
potency of microcystin toxins in cancer cells has been diffi-
cult to examine due to the absence of expression of these 
transporters in most cancer cell lines. However, there is evi-
dence for the expression of these transporters in tumors. 60 
Western blot analyses have detected the expression of both 
OATP1B1 and OATP1B3 in hepatocellular carcinoma (5, 6). 
Also, Abe et a!. (7) have reported that OATP1B1 and 
OATP1 B3 are expressed in a few cell lines created from liver, 
colon, and pancreatic tumors, suggesting that there may be a 65 
wider distribution of transporter gene expression in tumors 
than in normal tissues. 
Another aspect of the invention contemplates a combina-
tion therapy wherein a microcystin is used in combination 
with other cancer treatment modalities as known in the art. 
The present invention also provides a method of screening 
for a microcystin with improved cytotoxicity, using cells 
transfected with at least one of OATP1B1 and OATP1B3. 
Preferably, the cells are transfected with OATP1B3. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1. Scatter plots displaying the expression levels of 
OATP1B3 (A), THTR2 (B) and OATP1A2 (C) for each of the 
19 individual lung tumors(.._) and normal tissue C•) pairs. 
The solid line shows the median of the data set, whilst the 
dotted lines display the expression level in a reference sample 
from a normal tissue known to express the gene of interest. 
The data presented are expression level of each individual 
sample following normalization to ~-actin. 
FIGS. 2A-2B. Expression levels of OATP1B1 and 
OATP1B3 in normal liver, transfected HeLa cells, immortal-
ized hepatocyte cell lines, hepatocellular carcinoma cells 
(HCC), and lung cancer cell lines. Cells were collected and 
DNase treated RNA isolated as described in the Materials and 
Methods. Following eDNA synthesis, expression levels of 
OATP1B1 (A) and OATP1B3 (B) were analyzed using quan-
titative real-time PCR; ~-actin levels were used to normalize 
the expression. The data presented are the Mean±SD of dupli-
cate analysis. Protein phosphatases PP1 and PP2A are ubiq-
uitously expressed in all of the cell lines. Whole celllysates of 
Lung cancer (C) Hepatocellular carcinoma (D) cell lines, 
with HeLa cells used as a reference, were taken and equal 
amounts (25 flg/lane) of total protein were separated on a 10% 
SDS-PAGE gel, transferred to Nitrocellulose and immunob-
lotted for both PP1 and PP2A as described in the Materials 
and Methods. ~-actin was used to demonstrate equal loading. 
FIGS. 3A-3D. Uptake of radiolabeled OATP1B1 and 
OATP1B3 substrates. Cells were seeded in 6 well plates, 
transfected and assayed for uptake 48 hours later as described 
in the Material and Methods. A. [3H]-BQ123 (0.5 f.LM for 30 
minutes), a substrate ofboth OATP 1 B 1 and OATP 1 B3 and B. 
[
3 H]-CCK8 (5 nM for 10 minutes), a substrate specific for 
US 9,006,173 B2 
3 
OATP1B3, both substrates were also co-incubated in the 
presence of the competitive substrate BSP (50 f.LM). The data 
shown are the mean±SD of 3 replicate experiments. (C) 
Growth inhibition of OATP1B1 (circles) and OATP1B3-
transfected HeLa cells (triangles), and mock-transfected 5 
HeLa cells (squares) exposed to microcystin LR in the pres-
ence (open symbols) and absence (filled symbols) of the 
uptake inhibitor BSP. The cells were seeded in 96 wells plates 
24 hours following transfection with either the control plas-
mid piRESneo2, OATP1B1 or OATP1B3 containing vectors. 10 
Twenty-four hours after seeding, the cells were exposed to a 
range of microcystin LR concentrations for 72 hours with or 
without the competitive transport substrate BSP (50 f.LM). 
Growth inhibition was determined using the SRB dye assay 
as described in the Materials and Methods and data are pre- 15 
sented as the percent of untreated control growth. The data 
shown are the mean±SD. of 3 replicate experiments. (D) 
Clonogenic survival of HeLa cells transfected with 
piRESneo2 C•), OATP1B1 (e)orOATP1B3 (T) following a 
72 hour exposure to microcystin LR. The data shown are the 20 
mean±SD. of3 replicate experiments. (E) Growth inhibition 
ofOATP1B1-transfected HeLa cells exposed to microcystin 
LR for 1 C•), 6 (.._)and 72 (T) hours. Growth inhibition was 
determined using the SRB dye assay and data are presented as 
the percent of untreated control growth. The data shown are 25 
the mean±SD. of3 replicate experiments. 
FIGS. 4A-4C. Correlations between growth inhibition and 
in vitro enzyme inhibition (data from Table 2). The relation-
ship between the growth inhibition IC50 for the microcystin 
analogs and the in vitro enzyme inhibition IC50 ofPP2A (A), 30 
and PP1 (B). The filled circles (e) represent the microcystin 
analogs LW, LF, RR, and YR. The open square (D) is micro-
cystin LR, and the closed square C•) is okadaic acid. The 
Linear regression analysis was performed using the GRAPH-
PAD PRISM® Software. Inhibition of total phosphatase 35 
activity in transfected HeLa cells exposed to equitoxic con-
centrations (IC90) of the microcystin analogs (C). Intra-cel-
lular phosphatase enzyme inhibition was determined using 
whole cell lysates prepared from transfected HeLa cells 
exposed to IC90 concentrations of the Microcystinanalogs for 40 
6 hours as described in the Materials and Methods. 20 ng of 
cellular protein was incubated in phosphatase assay buffer in 
the presence of [33P]-ATP labeled MyBP for 10 minutes, after 
which the reaction was stopped with TCA and released [33P] 
was determined by liquid scintillation counting. The data are 45 
presented as the percent phosphatase activity relative to 
untransfected and untreated He La cells. All data are presented 
as the mean±SD. of3 replicate experiments. 
FIGS. SA -SI. Cell death induced by 1 0 nM microcystin LR 
(MC-LR) 6 hours after treatment. UntreatedOATP1B1 trans- 50 
fected HeLa cells (Panels A, Band C), 10 nM treated vector 
control (piRESneo2) transfected HeLa cells (Panels D, E and 
F), and 1 0 nM treated OATP 1 B 1 transfected He La cells (Pan-
els G, Hand I). Brightfield images used to visualize cellular 
morphology (Panels A, D and G). Fluorescent images show- 55 
ing Hoechst 33258 stain to visualize nuclear morphology and 
DNA condensation (Panels B, E and H), Flow cytometry plots 
4 
lines and tumor masses excised from untreated athymic nude 
mice 5 and 13 days after implantation. HeLa/piRES is a 
control cell line that contains an empty expression vector. 
Expression levels in the OATP1B1 tumors are comparable 
with the levels seen in the OATP1B1 cell line. 
FIG. 8. OATP1B1-expressing cancer cells were injected 
into the flanks of athymic nude mice. After palpable tumors 
were formed, cohorts were either injected with saline 5 days 
per week with saline (controls, 'saline QDx5', squares); 
injected with microcystin LR 25 flg/kg 5 days per week 
(MCLR QDx5, triangles); or injected withmicrocystin LR 35 
flg/kg every other day (MCLR QOD, diamonds). Tumors 
were measured every two days. The results represent the 
average±SD of cohorts of 3 or 4 mice. 
DETAILED DESCRIPTION OF THE INVENTION 
Our interest in microcystins as potential therapeutic mol-
ecules began with our finding that OATP1B3 mRNA is up-
regulated in non-small cell lung cancer (NSCLC). Therefore, 
the anticancer potential of microcystin compounds might be 
exploited by targeting these compounds to tumors that are 
known to express OATP1B1 and OATP1B3. 
Given that the microcystins are potent protein phosphatase 
inhibitors, they are likely to affect both cell cycling and apo-
ptosis. PP1 and PP2A directly regulate the activity of proteins 
phosphorylated on serine or threonine residues. PP2A has 
been shown to regulate the activity of at least 50 protein 
kinases involved in critical aspects of the regulation of cell 
division and cell death, including PKC, Akt, ERK, MEK, I KB 
kinase, p38 and caspase-3 (8-10). Inhibition of PP2A (by 
okadaic acid) has been shown to increase the phosphorylation 
and subsequent activation of p53 leading to cell cycle arrest 
and apoptosis (11, 12). Recent studies have identified PP2A 
as a key regulator ofBCL-2 (13). Pharmacological inhibition 
or RNAi knockdown of PP2A caused proteasomic degrada-
tion ofphosphoryated BCL-2 and sensitized the cells to vari-
ous cell death stimuli. Therefore, we hypothesized that tumor 
cells might be selectively sensitive to microcystin-induced 
phosphatase inhibition. To test this hypothesis we transfected 
cancer cells with the drug transporters OATP1B1 and 
OATP1B3 to create in vitro models in which microcystins 
could gain intracellular access, and the potential cytotoxicity 
of microcystins in cancer cells could be assessed. 
As used herein, the term "cancer" is meant to include 
tumors, such as primary tumors that are the original neo-
plasm. The term "cancer" is also meant to include metastatic 
disease, metastases, and metastatic lesions, which are groups 
of cells that have migrated to a site distant relative to the 
primary tumor. 
The term "cancer" embraces a collection of malignancies 
with each cancer of each organ consisting of numerous sub-
sets. Typically, at the time of cancer diagnosis, the "cancer" 
consists in fact of multiple subpopulations of cells with 
diverse genetic, biochemical, immunologic, and biologic 
characteristics. 
Preferably, the cancer is malignant. 
of Side scatter (SSC) versus Forward scatter (FSC) displaying 
the changes in cell size and the formation of cell fragments 
(Panels C, F and I). 
FIG. 6. The structure ofmicrocystin LR. The positions of 
the two variable amino acids leucine (L) and arginine (R) that 
are specific for microcystin LR are shown. 
The types of cancers to be treated by the methods of the 
instant invention are those that exhibit at least one of the 
60 organic anion transporters OATP1B1 and OATP1B3. Prefer-
ably, the cancers exhibit OATP1B3. 
FIG. 7. OATP1B1 RNA levels determined using quantita-
tive reverse transcription polymerase chain reaction (RT 65 
PCR) and normalized to the expression of~ -actin. OATP 1 B 1 
levels were analyzed in the in the stable in vitro HeLa cell 
Preferred cancers include but are not limited to hepatocel-
lular cancer, gastrointestinal cancer, lung cancer, gastric can-
cer, colon cancer, pancreatic cancer, gall bladder cancer, 
breast cancer, glioblastoma, and metastatic cancers and intra-
peritoneal disseminations thereof. The hepatocellular cancer 
can be hepatocellular carcinoma. The gastric cancer can be 
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signet ring cell cancer of the stomach, signet ring carcinoma, 
or rubular adenocarcinoma. More preferred cancers are hepa-
tocellular cancer, gastrointestinal cancer, and non-small cell 
lung cancer. 
The microcystin can be a substrate of and thus target one or 
both of the organic anionic transporters OATP1B1 and 
OATP1B3. Preferably, the microcystin is a substrate of 
OATP1B3. 
The microcystins contemplated for use in treating the 
above cancers may include compounds with the basic struc-
ture cyclo (D-Ala-X-erythro-~-methyl-D-iso-Asp-Y-Adda­
D-iso-Glu-N-methyldehydro-Ala), where X andY represent 
variable amino acids, andAdda is the ~-amino acid, 3-amino-
9-methoxy-2,6,8-trimethyl-1 0-phenyldeca-4,6-dienoic acid. 
Preferably, X andY are L amino acids. 
The microcystins can be naturally-occurring. At least fifty 
naturally-occurring microcystin analogs are known (WHO, 
Geneva: World Health Organization 1998:95-110). A pre-
ferred naturally-occurring microcystin is microcystin LR 
(FIG. 5), in which X is leucine andY is arginine. Naturally-
occurring microcystins can be isolated from natural sources, 
or can be synthetic structural equivalents of microcystins that 
can be isolated from natural sources. 
6 
The present invention also contemplates microcystins with 
improved cytotoxicity with regard to the organic anion trans-
porter OATP1A2, which is also known to mediate the cellular 
uptake of microcystins. For example, if the cancer exhibits 
OATP1B3, it may be beneficial to treat a patient with an 
improved microcystin analog that is a substrate for 
OATP1 B3, but has reduced affinity (including no affinity) for 
OATP1A2 and/or OATP1Bl. 
Particularly referred microcystins with improved cytotox-
10 icity are microcystin LF, in which X is leucine and Y is 
phenylalanine, and microcystin LW, in which X is leucine and 
Y is tryptophan. 
The microcystins can be used alone, in combination with 
each other, or in combination with other cancer modalities, 
15 such as but not limited to chemotherapy, surgery, radio-
therapy, hyperthermia, immunotherapy, hormone therapy, 
biologic therapy (e.g., immune effector mechanisms resulting 
in cell destruction, cytokines, immunotherapy, interferons, 
interleukin-2, cancer vaccine therapy, and adoptive therapy), 
20 and drugs to ameliorate the adverse side effects of such cancer 
modalities. 
As described herein, microcystins form a family of struc-
turally related cyclic peptides. An individual member of the 
microcystin family can be referred to variously herein as a 
"microcystin," a "microcystin analog,'' a "microcystin vari-
ant," or a "microcystin compound." 
The terms "treating", "treatment", and the like are used 
herein to generally mean obtaining a desired pharmacological 
and physiological effect. More specifically, the reagents 
described herein which are used to treat a subject with cancer 
generally are provided in a therapeutically effective amount 
to achieve any one or more of the following: inhibited tumor 
growth, reduction in tumor mass, loss of metastatic lesions, 
inhibited development of new metastatic lesions after treat-
The present invention also contemplates the use of novel 25 
synthetic microcystins for treatment of cancer. Novel syn-
thetic microcystin analogs having beneficial biological 
effects can be designed using combinatorial engineering. A 
person of ordinary skill in the art will recognize that there are 
various methods applicable to microcystin synthesis, includ- 30 
ing solid phase peptide synthesis. Examples are described in 
the literature, including Aggen et a!., Bioorg Med Chern 
1999; 7:543-564; Gulledge et a!., Bioorg Med Chern Lett 
2003; 13:2903-2906; and Gulledge eta!., Bioorg Med Chern 
Lett 2003; 13:2907-2911. 35 ment has started, or reduction in tumor such that there is no 
detectable disease (as assessed by, e.g., radiologic imaging, 
biological fluid analysis, cytogenetics, fluorescence in situ 
hybridization, immunocytochemistry, colony assays, multi-
parameter flow cytometry, or polymerase chain reaction). The 
The present invention also contemplates the use of micro-
cystins with improved cytotoxicity, i.e., microcystins having 
at least one of an improved cytotoxic potency or improved 
cytotoxic selectivity as compared to microcystin LR. 
Microcystins with improved cytotoxic potency, or greater 
cytoxic potency than microcystin LR, demonstrate IC50 val-
ues lower than the IC50 values of microcystin LR in cells 
transfectedwithOATP1B1 andlorOATP1B3, with no signifi-
cant increase in toxicity in control cells. Preferably, micro-
cystins with improved cytotoxic potency demonstrate IC50 
values lower than the IC50 values of microcystin LR in cells 
transfected with OATP1B3. Examples of microcystins with 
improved cytotoxic potency are microcystin LF and micro-
cystin LW, as shown in the present Examples. 
Microcystins with improved cytotoxic selectivity as com-
pared to the selectivity of microcystin LR demonstrate an 
improved differential toxicity between cells transfected with 
OATP1B1 as compared to OATP1B3. Because the present 
invention contemplates treatment of cancers expressing 
OATP1B3 and not OATP1B1, cancers expressing OATP1B1 
and not OATP1B3, and cancers expressing both transporters, 
a person of ordinary skill in the art will readily recognize that 
the definition of an "improved" differential toxicity will vary 
with the particular cancer to be treated. Preferably, micro-
cystins with improved cytotoxic selectivity demonstrate an 
increased relative cytotoxicity in cells transfected with 
OATP1B3 as compared to cells transfected with OATlBl. 
Examples of microcystins with increased relative cytotoxic-
40 term "treatment", as used herein, covers any treatment of a 
disease in a mammal, particularly a human. 
The term "subject" or "patient" as used herein is meant to 
include a mmal. Preferably the mammal is human. 
The term "pharmaceutically effective" as used herein 
45 refers to the effectiveness of a particular treatment regime. 
Pharmaceutical efficacy can be measured based on such char-
acteristics (but not limited to these) as inhibition of tumor 
growth, reduction of tumor mass, reduction of metastatic 
lesions as assessed, for example, by radiologic imaging, 
50 slowed tumor growth, lack of detectable tumor associated 
antigens, and the like. Additional methods of assessing tumor 
progression would be known to the treating and diagnosing 
physicians. 
By "pharmaceutically effective amount" is meant an 
55 amount of an agent, reagent, compound, composition, or 
combination of reagents disclosed herein that when adminis-
tered to a mammal is sufficient to be effective against the 
cancer. 
The present invention contemplates the use of microcystins 
60 in combination with other cancer modalities or treatments. 
ity in cells transfected with OATP1B3 as compared to cells 
transfected with OAT1B1 are microcystin LF, microcystin 65 
LW, microcystin RR, and microcystin YR, as shown in the 
present Examples. 
Many treatments exist for cancers. The particular cancer 
therapy or combination of therapy modalities used to treat a 
cancer depend greatly on the type of cancer, its stage, the 
patient (e.g., weight, sex, age, health, prior cancers, and the 
like), and where the patient is in therapy (e.g., first treatment, 
in blast crisis, refractive to initial treatments, cancer relapse, 
or a second cancer perhaps induced by the treatment of the 
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first cancer months or years before). Therefore, physicians 
will frequently have to combine a variety of treatment modali-
ties that will best suit the needs of the patient in combating the 
disease and the patient's self-determination of quality oflife. 
Treatment modalities include but are not limited to surgery, 
radiation therapy, chemotherapy, biologic therapy (e.g., 
cytokines, immunotherapy, and interferons), hormone thera-
pies, and hyperthermia. 
8 
According to one aspect of the invention, a microcystin 
may be administered alone, or in combination with other 
agents as discussed above to treat and/or ameliorate a cancer. 
Administration of other cancer therapeutic agents can occur 
prior to, concurrent with, or after administration with the 
microcystins. Administration of the microcystins can occur 
before, during or after surgical treatment, radiotherapy, hor-
mone therapy, immunotherapy, hyperthermia, or other cancer 
treatment modality. Administration of the microcystins can 
10 occur daily, weekly, or monthly as needed. 
Conventional chemotherapy can be further broken down 
into hormone therapies (e.g., anti estrogens, aromatase inhibi-
tors, gonadotropin-releasing hormone analogues, and anti-
androgens), anti-tumor alkylating agents (e.g., mustards, 
nitrosoureas, tetrazines, and aziridines ), cisplatin and its ana-
logues, anti-metabolites (e.g., methotrexate, antifolates, 
5-fluoropyrimidines, cytarabine, azacitidine, gemcitabine, 
6-thipurines, and hydroxyurea), topoisomerase interactive 
agents, antimicrotubule agents (e.g., vinca alkaloids, taxanes, 
and estramustine ), differentiating agents (e.g., retinoids, vita-
min D3, polar-apolar compounds, butyrate and phenylac- 20 
tetate, cytotoxic drugs, cytokines, and combinations thereof), 
and other chemotherapeutic agents such as fludarabine, 
2-chlorodeoxyadenosine, 2'-deoxycoformycin, homohar-
ringtonine (HHT), suramin, bleomycin, and L-asparaginase. 
One aspect of the invention contemplates a method of 
screening for microcystins with improved cytotoxicity. 
Microcystins with improved toxicity are described above. 
The present invention contemplates using cells transfected 
15 with at least one ofOATlBl and OAT1B3 to determine the 
Furthermore, the present invention contemplates delivery 25 
of the microcystins in combination with drugs (such as 
N -acetyl cysteine) that may selectively detoxifY microcystins 
in hepatocytes but not in cancer cells, in order to decrease the 
hepatotoxicity of microcystin treatment. 
The microcystins of interest discussed above preferably are 30 
administered as pharmaceutical compositions comprising 
pharmaceutically acceptable carriers, diluents, and/or excipi-
ents, which are vehicles commonly used to formulate phar-
maceutical compositions for animal or human administra-
tion. The carriers, diluents and/or excipients are not intended 35 
to have biological activity themselves, and are selected so as 
not to affect the biological activity of the microcystins and 
any other active agent(s ). A pharmaceutically acceptable car-
rier, diluent, and/or excipient as used herein includes both one 
and more than one such carrier, diluent, and/or excipient. 40 
Examples include but are not limited to distilled water, physi-
ological phosphate-buffered saline, Ringer's solutions, dex-
trose solution, and Hank's solution. 
Depending upon the manner of introduction, the micro-
cystins may be formulated as, for example, sterile injectable 45 
formulations comprising aqueous solutions and/or suspen-
sions containing the active materials in admixture with suit-
able carriers, diluents, and/or excipients. Formulations for 
oral use may be in the form of tablets or capsules. 
The concentration of therapeutically active microcystins in 50 
the formulation (i.e., a formulation that is therapeutically 
effective to the subject to which it was administered) and the 
dose administered can be readily determined by a person of 
ordinary skill in the art. Typically, dosages used in vitro and in 
animal models may provide useful guidance in the amounts 55 
useful for in vivo administration. Preferably, the dose admin-
istered will be less than the hepatotoxic dose. 
The microcystins may be administered locally or systemi-
cally in a therapeutically effective dose. 
The methods of administration include but are not limited 60 
cytotoxicity of candidate microcystin analogs. In one aspect 
of the invention, transfected cells are treated with the micro-
cystin, followed by determination of cell growth. In another 
aspect of the invention, phosphatase inhibition in the micro-
cystin-treated cells is measured. 
It must be noted that as used herein, the singular forms "a", 
"and", and "the" include plural referents unless the context 
clearly dictates otherwise. Thus, for example, reference to "a 
microcystin" or "microcystin analog" includes a plurality of 
such microcystins or microcystin analogs, and reference to 
"the dosage" includes reference to one or more dosages and 
equivalents thereof known to those skilled in the art, and so 
forth. 
EXAMPLES 
Abbreviations 
OATP, Organic Anion Transporting Polypeptide; PPl, pro-
tein phosphatase-!; PP2A, protein phosphatase-2A; LST, 
Liver Specific Transporters; NSCLC, non-small cell lung 
cancer; PKC, Protein Kinase C; Akt, Protein Kinase B, ERK, 
extracellular signal-regulated kinases, MEK, MAPK kinase, 
IKB kinase, Inhibitor of KB kinase; DMEM, Dulbecco's 
Modified Eagles Medium; FBS, fetal bovine serum; DOC, 
Sodium deoxycholate; TBS, Tris buffered saline; CCK-8, 
Cholecystokinin Octapeptide; BSP, Bromosulfophthalein; 
SRB Sulforhodamine B; TCA, Trichloracetic Acid; DTT, 
dithiothreitol; MyBP, Myelin Basic Protein; JNK, c-Jnn 
N-terminal kinase; NAC, N-acetylcysteine; BSO, buthionine 
sulfoximine; SSC, Side scatter: FSC, Forward scatter. 
Materials and Methods 
Reagents and Cell Culture. 
HeLa cervical adenocarcinoma cells were obtained from 
the American Type Culture Collection (Manassas, Va.). Dul-
becco's Modified Eagles Medium (DMEM) containing 
GLUTAMAX™-I, fetal bovine serum (FBS), phosphate 
buffered saline (PBS) pH 7.2 and LIPOFECTAMINE™ 2000 
were purchased from Gibco (Carlsbad, Calif.). Lung tumor 
specimens and matched adjacent non-malignant tissue pairs 
were obtained from the NCI Cooperative Human Tissue Net-
work (CHTN; Columbus, Ohio). Normal liver eDNA was 
purchased from Biochain Institute, Inc (Hayward, Calif.). 
Microcystins LR and YR were purchased from Sigma, (St 
Louis, Mo.). Microcystin LF, LW, RR and Okadaic acid were 
all purchased from Axxora, LLC (San Diego, Calif.). 
[
33P]-ATP was purchased from PerkinElmer (Boston, Mass.). 
All other chemicals were purchased from Sigma. 
to parenteral administration, including subcutaneous (s.c.), 
subdural, intravenous (i.v.), intramuscular (i.m.), intrathecal, 
intraperitoneal (i.p.), intracerebral, intraarterial, intrale-
sional, and pulmonary (e.g., via aerosols, inhalation, or pow-
der) routes of administration. Administration can be via sur-
gical application or surgical suppository. Oral administration 
is also contemplated. 
Transporter Gene Expression Analysis by Quantitative 
65 PCR. 
A protocol to screen anonymous lnng tumor specimens for 
transporter gene expression was approved by the University 
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of Kentucky Institutional Review Board. For each transporter 
gene, we identified a primer set using the program Oligo 4.0. 
In each case we demonstrated that the primers amplifY a PCR 
product of expected length. Total RNA was extracted from 
normal lung tissue and paired lung cancer specimens and cell 5 
lines using the RNEASY kit (QIAGEN) with an on-column 
DNase digestion. A total of 3 flg of RNA was used as a 
template for the first-strand eDNA synthesis using the THER-
MOSCRIPT™ RT-PCR system (Invitrogen, Carlsbad, Calif.) 
with Oligo( dT) as the primer and performed according to the 10 
manufacture's protocol. Quantitative real-time PCR was per-
formed using the SYBR® Green PCR Kit (Applied Biosys-
tems; Foster City, Calif.) and the iCyclerthermal cycler (Bio-
Rad). Quantification was performed using iCycler analysis 
software. The fluorescence threshold was set above the base- 15 
line in the exponential phase of the PCR and from this the Ct 
(threshold cycle) was calculated for each reaction. The num-
ber of cycles required to reach the threshold fluorescence is 
proportional to the amount target RNA in the sample. The 
relative expression levels of the target genes were determined 20 
by calculating the relative amounts of RNA from PCR stan-
dard curves (eDNA from liver, kidney or placenta was used as 
standards for the lung tissue expression analysis, plasmid 
DNA was used to for the cell line expression analysis), fol-
lowed by normalization to the endogenous reference gene 25 
~-actin. All PCR products of the samples displayed a single, 
sharply melting curve with a narrow peak. Both OATP1B1 
and OATP1B3 share >80% homology at the nucleotide level, 
therefore primer specificity was confirmed by the inclusion of 
a negative control to each analysis, (plasmid containing the 30 
alternative gene). Neither of the primer sets amplified the 
other gene. 
Transient Expression ofOATP1B1 and OATP1B3. 
OATP1B1 andOATP1B3 cDNAsinsertedintothemultiple 
cloning site ofthevectorpiRESneo2 were obtained from Drs. 35 
Meier and Hagenbuch at the University of Zurich, and the 
nucleotide sequences of the coding regions were confirmed 
by nucleic acid sequencing. 
Exponentially growing HeLa cells were seeded at 2x105 
cells/well in 6-well plates in 2 ml of DMEM supplemented 40 
with 5% fetal calf serum (without antibiotics). The cells were 
transfected 24 hours later using LIPOFECTAMINE™ 2000 
(Invitrogen) at a ratio oflipid:DNAof2:1 (2 f.tl: 1 flg). In short, 
2 fll of LIPOFECTAMINE™ 2000 diluted into 200 fll of 
OPTI-MEM® (Invitrogen), at the same time 1 flg of plasmid 45 
DNA is also diluted into 200 fll ofOPTI-MEM® and left to 
equilibrate for 5 minutes. The DNA and LIPO-
FECTAMINE™ 2000 dilutions were mixed by pipetting and 
complexes allowed to form for 25 minutes. During complex 
formation the cells were washed cells once with 37° C. PBS 50 
and 600 fll ofDMEM supplemented with 5% fetal calf serum 
was added to each well. After 25 minutes, the complex mix-
ture ( 400 fll) was carefully added to the cells, mixed gently, 
and the transfection allowed to proceed at 37° C., in 5% C02 
for 4 hours. After 4 hours 1 ml ofDMEM supplemented with 55 
10% fetal calf serum was added to each well and the cells 
returned to the incubator. 
Western Blot Analysis. 
10 
tein assay (Bio-Rad, Hercules, Calif.). Equal amount of pro-
tein (25 f.tg/lane) were separated by 10% SDS-polyacryla-
mide gel electrophoresis (PAGE) and subsequently 
transferred to PROTRAN BA85 nitrocellulose membrane 
(Whatman, Inc. Sanford Me.). The membranes were incu-
bated with antibodies against PP1 and PP2A (Santa Cruz 
Biotechnology, Inc. Calif.) in 5% non-fat milk. After washing 
with TBS-Tween the membranes were incubated with peroxi-
dase-conjugated goat anti-mouse or goat anti-rabbit antibody 
(Jackson Immunoresearch Laboratories, Inc., West Grove, 
Pa.) in 5% non-fat milk, followed by visualisation using the 
enhanced chemiluminescence system (Amersham Bio-
sciences, Piscataway, N.J.). ~-actin (Sigma) was used to con-
firm equal protein loading. 
Drug Uptake Studies. 
Exponentially growing HeLa cells were transiently trans-
fected with the plasmids containing OATP1B1, OATP1B3 or 
empty piRESneo2 as described above. 48 hours after trans-
fection, the cells were exposed to two commercially avail-
able, radio labeled substrates in uptake buffer (142 mM NaCl, 
5 mM KCl, 1 mM K2HPO 4 , 1.2 mM MgSO 4 , 1.5 mM CaC12 , 
Glucose5mMandHEPES 12.5mM-pH7.3): [3H]-BQ123 
(Amersham Biosciences, N.J.) for 30 minutes (final concen-
tration 0.5 f.LM), a substrate for both transporters (14) and 
[
3 H]-CCK-8 (Cholecystokinin Octapeptide, Amersham Bio-
sciences) for 10 minutes (5 nM), a substrate specific for the 
OATP1B3 transporter (14). The uptake assay was terminated 
by aspiration of the medium and three successive washes with 
ice-cold PBS. The cells were air dried and solubilized by 
overnight incubation in 0.2 N NaOH, followed by neutraliza-
tion with 0.2 N HCI. The amount of intracellular radioactivity 
in the lysates was determined by liquid scintillation counting. 
The results were calculated by the subtraction of time-zero 
counts followed by normalization to the amount of cellular 
protein present in the lysates, which was determined spectra-
photometrically using the Bio-Rad protein assay. Inhibition 
of transport was performed by coincubation with 50 f.LM 
bromosulfophthalein (Sigma). 
Growth Inhibition Studies. 
Cells were taken 24 hours following transfection and 
seeded into 96 well plates at 1 x104 cells/ml (1 x1 03 cells/well) 
and allowed to adhere for a further 24 hours prior to drug 
treatments. The cells were then exposed to serial dilutions of 
the microcystin analogs prepared in culture medium for 72 hr. 
Experiments in which cells were exposed to microcystin LR 
for 1 and 6 hours, the media was carefully aspirated from the 
wells and replaced with 200 fll of fresh media. Cellular 
growth was determined using the sulforhodamine B (SRB) 
protein dye assay (15). In short, cells were fixed with 50% 
TCA w/v (50 fll/well) for 1 hour at 4 o C. Following fixation, 
the plates were washed 5-6 times in water and stained with 
SRB (0.4% SRB (w/v) in 1% (v/v) acetic acid) for30minutes 
at 37° C. Excess stain was removed by washing 5 times in 1% 
(v/v) acetic acid. The plates were subsequently air-dried and 
the protein-bound SRB re-solubilized by the addition of 10 
mM Trizma Base, pH 1 0.5. Colorimetric readings were made 
at 570 nm. The IC50 was calculated from the dose response 
curve as the concentration of drug that produced a 50% 
decrease in the mean absorbance compared to the untreated Cells were washed twice in ice-cold PBS, lysed without 
trypsinisation for 10 minutes at 4 o C. using a lysis buffer 
containing 150 mMNaCl, 50 mMTris.Cl, pH 8.0, 1% NP-40, 
0.5% DOC, 0.1% SDS and 0.02% sodium azide and 80 fll/ml 
60 wells. 
of Complete Protease Inhibitor cocktail (Roche Applied Sci-
ence, Indianapolis, Ind.). Samples were passed through a 
25-gauge needle 10 times, and the lysate collected following 65 
centrifugation at 12,000 g for 5 minutes at 4° C. Protein 
concentrations were determined using the Bio-Rad DC pro-
Clonogenic Survival Studies. 
HeLa cells were transiently transfected with OATP1B1, 
OATP1 B3 or empty piRESneo2 as described above. 48 hours 
after transfection, cells were seeded into 60 mm culture 
dishes at 200 cells/dish in 5 ml of media. 6 hours after seed-
ing, microcystin LR was added to duplicate dishes and left for 
a further 72 hours. Following microcystin LR exposure, the 
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media was careful aspirated from the dishes and replaced with 
5 ml offresh media. The dishes were left for approximately 7 
days until colonies were visible, at which time the cells were 
washed once with PBS, fixed using Camoy's Fixative 
(methanol:acetic acid-3: 1) for 5 minutes and stained using 
0.4% crystal violet dissolved in water. The number of colo-
nies on each plate was counted by eye and survival calculated 
12 
as the percentage of control. The LC50 was extrapolated from 
the graph and is defined as the concentration at which the 
number of colonies was 50% of the control. The cloning 
efficiency is each transfected cell line was >95%. 
Inhibition of Purified Protein Phosphatases. 
Phosphatase activity was determined using the Protein 
Serine/Threonine Phosphatase (PSP) Assay System (New 
England BioLabs Inc. MA). The in vitro activity of purified 
PP1 (New England Biolabs) and PP2A (Upstate Cell Signal-
ing Solutions, NY) was assayed according to the manufac-
turers instructions. Briefly, PP1 or PP2A were diluted in 
phosphatase assay buffer (50 mM Tris-HCl (pH 7.5), 0.1 mM 
Na2EDTA, 5 mM DTT and 0.01% Brij 35) at a concentration 20 
were the enzyme concentration is linear with dephosphory-
lation (""30%) of the [33P]-ATP labeled Myelin Basic Protein 
(MyBP). The inhibitory effects of okadaic acid and the micro-
cystin analogs, was determined by pre-incubation of the 
enzymes with serial dilutions of each compound for 10 min- 25 
utes prior to the addition of the radio labeled substrate. [33P]-
MyBP was added to the reaction (final reaction volume 50 fll) 
and immediately incubated at 30° C. for 10 minutes. The 
reaction was stopped by the addition of 200 fll of ice-cold 
20% TCA and incubated for a further 10 minutes on ice. The 30 
precipitated protein was pelleted by centrifugation at 12,000 
pooled and washed once with ice cold PBS. Cells were then 
either fixed in Carnoy's fixative or live cells immediately 
analyzed by flow cytometry, (SSC-side scatter (granularity) 
versus FSC-forward scatter (relative size), to determined 
changes in gross cell morphology relative to a control (un-
treated) population. Flow cytometry was performed using a 
BD FACSCALIBUR™ system (BD Biosciences, NJ). Fixed 
cells were stained with Hoechst 33258 (1 flg/ml dissolved in 
PBS) and changes in nuclear/DNA morphology were deter-
10 mined by fluorescent con-focal microscopy. Brightfield and 
fluorescent images were taken under a 40x oil immersion 
objective using a confocal Leica DM IRBE inverted micro-
scope equipped with a Spectra-Physics 2 photon sapphire/ 
15 titanium laser and transmitted light detector for differential 
interference contrast and phase microscopy. 
g at 4 o C. for 5 minutes, following which 200 fll of the 
supernatant was carefully removed and the amount of 
released 33P determined by liquid scintillation counting. The 
data were normalized to a duplicate control reaction per- 35 
formed in the absence of the phosphatases. The IC50 was 
calculated as the concentration of drug that inhibited the 
release of 33P compared to an uninhibited control reaction. 
Intracellular Protein Phosphatase Analysis. 
To determine the effects of the microcystins on the activity 40 
of the intracellular phosphatases in the transiently transfected 
HeLa cells, celllysates were prepared as follows. 48 hours 
following transfection, HeLa cells transfected with either 
piRESneo2, OATP1B1 or OATP1B3 were treated with 
microcystin analogs and okadaic acid at approximately IC90 45 
concentrations for 6 hours. The cells were subsequently 
washed in ice-cold PBS and 500 fll of the phosphatase assay 
buffer containing 80 fll/ml of Complete Protease Inhibitor 
cocktail was added to each well, the cells were immediately 
scraped, collected in 1.5 ml microcentrifuge tubes and freeze/ 50 
thawed twice in dry-ice/room temperature water. The cells 
were further lysed by repeated pipetting (x10) and immedi-
ately centrifuged at 12,000 g for 10 minutes at 4° C. The 
remaining supernatant was collected and frozen at -80° C. 
The protein concentration of the cell lysates was measured 55 
using the Bio-Rad protein assay. To determine the levels of 
phosphatase inhibition in the microcystin treated cells, 20 ng 
of cellular protein was incubated in phosphatase assay buffer 
in the presence of [33P]-ATP labeled MyBP as described 
above. The results are presented as the percent of total phos- 60 
phatase activity relative to untransfected untreated HeLa 
cells. 
Cellular and Nuclear Morphology Studies. 
HeLa cells were transiently transfected with OATP1B1 or 
empty piRESneo2 as described above. Forty eight hours after 65 
transfection, the cells were treated with 10 nM microcystin 
LR for 6 hours. Floating and adherent cells were subsequently 
Results 
Example 1 
OATP1B3 Expression is Increased in NSCLC 
Tumors Relative to Adjacent Non-Malignant Tissue 
We analyzed the expression of 19 drug and vitamin trans-
port genes in 19 pairs of NSCLC tumors and surrounding 
non-malignant tissue obtained from the NCI Cooperative 
Human Tissue Network. RNA extracted from tumors was 
analyzed for transporter gene expression using quantitative, 
real-time PCR and the results were normalized to the expres-
sion of ~-actin. The ratio between the expression in tumor 
compared to adjacent non-malignant tissue for each paired 
sample was calculated and the median value for the series of 
tumor-tissue pairs for each gene is presented in Table 1. 
TABLE 1 
Ratio of transporter gene expression in lung tumors compared 
to normal surrounding tissue 
Transporter Gene symbol Tumor/Normal Ratio 
OAT! SLC22A6 0.62 
OAT2 SLC22A7 0.90 
OAT3 SLC22A8 1.17 
OAT4 SLC22All 1.11 
OATP1A2 SLC21A3 1.28 
OATP1B3 SLC21A8 6.38 
OATP1C1 SLC21A14 0.68 
OATP2A1 SLC21A2 0.18 
OATP2B1 SLC21A9 0.47 
OATP3A1 SLC21All 0.95 
OATP4A1 SLC21A12 1.24 
OCT! SLC22A1 0.81 
OCT2 SLC22A2 0.36 
OCT3 SLC22A3 0.33 
OCTN1 SLC22A4 0.25 
OCTN2 SLC22A5 0.81 
RFC1 SLC19A1 0.78 
THTR1 SLC19A2 0.67 
THTR2 SLC19A3 0.35 
Table 1 shows relative expression levels of 19 drug and 
vitamin transport genes in 19 pairs ofNSCLC tumors com-
pared to surrounding non-malignant tissue, obtained from the 
NCI Cooperative Human Tissue Network. DNase treated 
mRNA was isolated from tissues as described in the Materials 
and Methods. Following eDNA synthesis, expression levels 
of each gene were analyzed using quantitative real-time PCR. 
~-actin levels were used to normalize the expression and data 
are presented as the ratio of the median tumor expression 
compared to the median of the paired normal tissue. 
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cell lines SNU-449, SNU-182 andHepB3. The SV40 immor-
talized hepatic cell lines THLE-2 and THLE-3 are also 
shown. 
Example 3 
HeLa Expression Models Exhibit Functional Activity 
and Confers Increased Sensitivity to Microcystin LR 
and Other Natural Microcystin Analogs 
To determine whether the RNA expression in transiently 
transfected HeLa cells resulted in functional activity of the 
transport genes, we studied the uptake of radiolabeled 
BQ123, a substrate for both OATP1B1 and OATP1B3 and 
The mRNA of only one gene, OATP1B3 was found to be 
up-regulated, by a median value of 6.4-fold in lung tumors 
compared to surrounding normal tissue; whereas all of the 
other transport genes showed little increase in expression. A 
number of genes did show a decrease in lung tumor expres- 5 
sian with the transporters OATP2A1, OCT2, OCT3, OCTN1 
and THTR2 all showing >3-fold drop in expression. The 
decrease RNA levels of THTR2 in this series is consistent 
with our previous study of THTR2 RNA levels in NSCLC, 
which used a different set ofNSCLC tumor/tissue pairs and a 10 
different methodology (hybridization of labeled probes to a 
eDNA array) (16), and which also found a decrease in THTR2 
RNA levels in NSCLC tumors relative to adjacent non-ma-
lignant tissue. 
15 CCK-8, a substrate specific for OATP1B3 only. As shown in 
FIG. 3, gene-specific uptake of BQ123 can be seen in both 
OATP1B1- and OATP1B3-transfected cells (panel A), and 
OATP1B3-specific uptake of CCK-8 can be seen in 
To further illustrate the changes in expression between 
tumor and normal lung tissue, representative scatter plots for 
OATP1B1 (A), THTR2 (B) and OATP1A2 (C) are shown in 
FIG. 1. The solid line represents the median value presented OATP1B3-transfected cells (panel B). In both cases, uptake 
activity was inhibited by an excess of BSP (50 f.LM), a known 
competitive inhibitor of these transporters. These studies 
demonstrate that the functional activity of the cloned, trans-
fected genes is consistent with the previously reported sub-
strate profile of these transporters (14 ). To determine whether 
in Table 1; the dotted line represents a reference sample 20 
showing the expression in a normal tissue known to express 
each gene. Of particular interest is the increased expression of 
OATP1B3 in a number of the lung tumor samples (FIG. lA) 
which is comparable to the expression level ofOATP1B3 in 
normal liver, 25 the functional expression ofOATP1B1 and OATP1B3 result 
in change sensitivity to microcystin LR, we exposed the trans-
fected HeLa cells to microcystin LR in a 72 hour growth 
inhibition assay. As can be seen in FIG. 3C, the IC50 for 
microcystin LR in OATP1B1 cells was 5±1 nM and the IC50 
Example 2 
HeLa Transient Transfection Model Demonstrates 
Equivalent Levels of Transporter Expression to Liver 
and PP1 and PP2A Expression Suitable for the Study 
of Microcystins 
To explore whether OATP1B3 expression could confer 
sensitivity to its toxic substrates (e.g. microcystin), and thus 
be exploited as potential target in lung cancer, hepatic cancer 
and other malignancies, a transgenic model ofOATP1B3 and 
the closed related gene OATP1B1 was needed. Because of 
their relative ease of transfection and capacity to express 
trans genes, we performed initial investigations in HeLa cells 
as a proof-of-principle. Exponentially growing HeLa cells 
were transiently transfected with the expression plasmids 
containing the OATP1B1 and OATP1B3 eDNA inserts, or a 
plasmid without a eDNA insert (vector control). To confirm 
the expression level of the cloned cDNAs and to determine 
the approximate level of expression in the transfected HeLa 
cells relative to both control cells and normal liver eDNA, we 
performed real-time-PCR as shown in FIG. 2 (panels A and 
B). These studies demonstrate that the RNA levels in the 
transient transfection system approximate the levels seen in 
normal adult liver. Of significant interest, we observed that 
the hepatic-derived cell lines have lost expression of these 
transporters in comparison to normal liver, and lung cancer 
cell lines also have either very low or undetectable levels of 
RNA expression of these transporter genes. 
30 for OATP1B3 cells was 39±8 nM, while the toxicity in the 
control cells was not reached at 10 f.LM. Similar results were 
seen using the clongenic assay (FIG. 3D), which again iden-
tified the differential sensitivity for microcystin LR between 
OATP1B1 (LC50=2nM) andOATP1B3 ((LC50=30nM), with 
35 no toxicity seen in the vector alone (piRESneo2) cells. These 
results demonstrate the potential selective toxicity that the 
expression of these transporter genes confer on HeLa cells 
after exposure to microcystin LR. 
To determine whether microcystin toxicity can be specifi-
40 cally inhibited in OATP1B1 and OATP1B3-transfected cells, 
we performed a growth inhibition study with microcystin LR 
in the presence or absence ofBSP. As can also be seen in FIG. 
3C, BSP significantly shifted the growth inhibition curve to 
the right, increasing the IC50 for both OATP1B1 and 
45 OATP1B3-transfected cells from 5 nM and 39 nM, respec-
tively, to approximately 5 f.LM, further confirming the role of 
OATP1B1 and OATP1B3 uptake in microcystin LR toxicity. 
To further understand the activity of microcystin LR, we 
exposed OATP 1 B 1-transfected He La cells to microcystin LR 
50 for 1, 6 and 72 hours (FIG. 3E). A 1 hour exposure was found 
to be less active, whilst the 6 hour exposure was similar to 72 
hours, identical results were obtained with OATP1B3-trans-
fected cells (data not shown). This result demonstrates that 
toxic effects of microcystin LR are rapid, reaching a maxi-
55 mum effect after only 6 hours of incubation. 
Since microcystins are known substrates ofOATP1B1 and 
OATP1B3 and are also acknowledged inhibitors ofPP1 and 
PP2A, it was important to demonstrate that HeLa, lung and 
hepatic cancer cells express PP1 and PP2A, Western blot 
analysis was performed using antibodies directed against PP1 60 
and PP2A (FIG. 2, panels C and D). This study demonstrates 
that both phosphatases are present in HeLa cells, indicating 
that HeLa cells would make an appropriate in vitro model 
system. The studies also show that PP1 and PP2A are present 
We subsequently examined four other microcystin analogs 
using growth inhibition assays in the transfected He La cells to 
determine whether there was evidence that different struc-
tural analogs had greater potency or selectivity than micro-
cystin LR. We also used okadaic acid, the classical phos-
phatase inhibitor that was not thought to have selective uptake 
requirements, as a positive control. As shown in Table 2, two 
of the analogs examined, microcystin LF and microcystin 
LW, showed greater cytotoxic potency than microcystin LR, 
with both demonstrating IC50 values in both of the gene-
transfected cell lines of less than 1 nM, with no evidence of 
in cell lines created from tumors that are known to express 65 
OATP1B1 andlorOATP1B3: the lung cancercelllinesA549, 
NCI-H460 and NCI-H23; and the hepatocellular carcinoma toxicity in the vector-only transfected cells at concentrations 
US 9,006,173 B2 
15 
up to 1 f.LM. Microcystin RR exhibited much less potent 
cytotoxicity, with an IC50 of 3.8±2.3 f.LM and 0.58±0.40 f.LM 
for OATP1B1 and OATP1B3-transfected cells, respectively. 
Still, the transporter gene expression increased cytotoxicity 
of microcystin RR, with the vector-transfected cells not 
showing any cytotoxicity at concentrations up to 10 f.LM. Both 
microcystins LR and RR demonstrated differential toxicity 
between the cells transfected with the either OAPT1B1 and 
OATP1 B3. This data demonstrates that structural variation in 
the microcystin analogs provides a degree of transporter 10 
selectivity. 
TABLE2 
Microcystin analog growth inhibition and protein phosphatase enzyme 
inhibition 
16 
Further evidence for the importance of selective phos-
phatase inhibition in cytotoxicity is provided in FIG. 4, which 
shows the correlation between the data in Table 2. FIGS. 4A 
and 4B show the relationship between the growth inhibition 
IC50 for the microcystin analogs and the in vitro enzyme 
inhibition IC50 ofPP2A and PP1, respectively, where micro-
cystin LR is represented by the open square (excluded from 
the linear regression analysis). In FIG. 4A, the near linear 
relationship between HeLa growth inhibition and PP2A 
enzyme inhibition (r>0.99) of 4 microcystin analogs (filled 
squares) suggests that the activity of these analogs in the 
Growth Inhibition Enzyme Inhibition 
Microcystin p!RESneo2 OATP!Bl OATP1B3 PPl PP2A 
analog IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) 
LR >10,000 5 ±51 39 ± 8 1.4±0.3 0.18 ± 0.01 
LF >1000 0.4 ± 0.1 0.9 ± 0.9 2.2 ± 1.5 0.30 ± 0.01 
LW >1000 0.3 ± 0.1 0.5 ± 0.4 3.1 ± 0.3 0.24 ± 0.02 
RR >10,000 3,800 ± 2,300 580 ± 400 6.9 ± 0.01 22.0 ± 7.0 
YR >1000 90 ± 20 45 ± 30 18.0 ± 6.0 3.3 ± 0.14 
Okadaic 7.8 ± 1.5 2.2 ± 0.6 3.0 ± 1.2 90 ± 17 0.40 ±0.18 
acid 
HeLa cells is related more to PP2A inhibition than PP1 (FIG. 
4B). Similar results were found in the HeLa cells transfected 
with OATP1B3 (data not shown). The relation between cyto-
toxicity and PP2A inhibition is further supported by the 
observation that the IC50s of the analogs for growth inhibition 
and PP2A enzyme inhibition are both in the same sub-nano-
molar range. The results with okadaic acid (closed square) 
further support this conclusion. 
We measured global phosphatase inhibition in the trans-
fected HeLa cells exposed to approximately equitoxic (IC90) 
concentrations of microcystins to further examine the rela-
In Table 2, growth inhibition was determined in plasmid 
transfected HeLa cells. Cells were seeded into 96 wells plates 30 
24 hours following transfection with control plasmid 
(piRESneo2), OATP1B1 or OATP1B3 containing vectors 
and 24 hours later exposed to a range of microcystin concen-
trations for a further 72 hours. Growth inhibition was deter-
mined using the SRB dye assay as described in the Materials 35 
and Methods. The IC50 data presented in the table represent 
the concentration at which the absorbance is 50% of the 
untreated control wells, the IC50 was determined by non-
linear regression (variable slope) analysis using the GRAPH-
PAD PRISM® software. Phosphatase enzyme inhibition was 
determined using purified PP1 and PP2A enzyme. Enzyme 
was incubated with the microcystins at a range of concentra-
tions for 10 minutes prior to the addition of[33P]-ATP labeled 
Myelin Basic Protein. The de-phosphorylation reaction was 
allowed to proceed for 10 minutes, after which the reaction 
was stopped with TCA and released [33P] was determined by 
liquid scintillation counting as described in the Material and 
Methods. The IC50 was determined by non-linear regression 
(variable slope) analysis using the GRAPHPAD PRISM® 
software and represents the concentration at which the release 
40 tionship between the cytotoxic effects and protein phos-
phatase inhibition. In these studies, OATP1B3-transfected 
HeLa cells and empty vector control cells were exposed for 6 
hours to the microcystins at approximately equitoxic concen-
trations, and phosphatase activity in the cellular cytosol was 
of [33P] was inhibited by 50% compared to the untreated 
enzyme control reaction. All data are presented as the 
mean±SD. of ;;:3 replicate experiments. 
Example 4 
Microcystins Demonstrate Both Potent and 
Differential Inhibition of Protein Phosphatases 
45 then measured. As can be seen in FIG. 4C, total phosphatase 
inhibition does not directly correspond to cytotoxicity. For 
example, at a dose of approximately 2-fold greater than the 
cytotoxic IC50 in OATP1B3-transfected HeLa cells, micro-
cystin LF and LW (1 nM) had no discernable effect on total 
50 phosphatase activity. At a similar equitoxic dose, microcystin 
LR (1 0 nM) decreased total phosphatase activity by approxi-
mately 30% in OATP1 B 1-transfected cells. However, micro-
cystin RR (1 f.LM) decreased total phosphatase activity by 
90%. These results suggest that specific phosphatase inhibi-
55 tion, not global inhibition, is related to cytotoxicity. These 
results also suggest that at higher concentrations, micro-
cystins may have inhibitory effects on other phosphatases. 
Example 5 
The in vitro analysis of microcystin inhibition on purified 60 
PP1 and PP2A phosphatases is also shown in Table 2. The 
values determined are consistent with previously reported Ki 
values for microcystin LR and okadaic acid. The reported Ki 
values for microcystin-LR against PP1 and PP2A are 0.06-6 
nM and <0.01-2 nM, respectively (17). Okadaic acid has a 65 
reported IC50 of 60-500 nM for PP1 and 15-70 nM for PP2A 
(18). 
Cell Death Induced by Microcystin LR is Rapid 
FIG. 5 displays the results of microcystin LR induced cell 
death after a 6 hour exposure. Using confocal microscopy and 
changes in cell morphology shown by flow cytometry we 
have identified that exposure to Microcystin LR induced 
rapid changes in cell and nuclear morphology. Initial mor-
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phologic changes are rapid detachment from the culture sur-
face, which occurs within the first hour of exposure (data not 
shown). By 6 hours microcystin LR-treated OATPlBl 
expressing cells, display membrane blebbing (FIG. SG), and 
massive cellular fragmentation can be detected using flow 
cytometry (FIG. 51). Using Hoechst 33258 DNA stain, we 
also identified extensive chromatin condensation and frag-
mentation (FIG. SH) following a 6 hour microcystin LR expo-
sure. Control (piRESneo2) transfectants similarly treated 
with 10 nM microcystin LR showed no changes in cellular 
morphology (FIGS. SD and F) and nuclear condensation 
(FIG. SE), comparable to the untreated OATPlBl-trans-
fected control (FIGS. SA, B and C), further supporting the 
evidence that microcystins require a transport mechanism for 
cellular uptake and toxicity. Taken together, these data dem-
onstrate that once microcystin LR gains entry into cells it acts 
rapidly causing morphological changes which are indicative 
of cell death. 
Example 6 
Xenograft Model 
Clones of HeLa cells that stably express both OATP1B3 
and OATPlBl have been isolated, and a preliminary study a 
preliminary study with stable OATPlBl-expressing HeLa 
cells transplanted into athymic nude mice has been con-
ducted. The OATPlBl gene was chosen for initial studies of 
hepatocellular carcinoma, a malignancy where OATPlBl is 
expressed. Our in vitro data indicates that both OATP 1 B 1 and 
OATP1B3 effectively mediate the uptake of microcystins, 
and can be expected to have similar function in vivo. We have 
also demonstrated that this cell line can grow in vivo and that 
the gene expression is maintained when grown as tumor 
xenografts (FIG. 7). 
Example 7 
OATPlBl-Expressing HeLa Xenografts Treated 
with Microcystin LR 
In this in vivo experiment of microcystin LR treatment, 
OATPlBl-expressing cancer cells were implanted subcuta-
neously in the flanks of 10 athymic nude mice and microcys-
tin LR was administered in two schedules by intraperitoneal 
(IP) injection after tumors were established (FIG. 8). A cohort 
of3 mice were injected with 35 flg/kg IP every other day and 
a second cohort of 3 mice received daily injections of 25 
flg/kg Monday through Friday. A cohort of 4 mice served as 
controls and were injected IP with saline. The doses and 
schedules were all the first approximations, and other micro-
cystin analogs are more potent in vitro. The graph shown in 
FIG. 8 shows the result of this first experiment, and demon-
strates the proof-of-principle that established OATPlBl-ex-
pressing tumors respond to microcystin treatment. The 
therapy was tolerated; all mice survived the treatment regi-
mens. The weight in the control group was 22.7±1.3 grams at 
day 0 and 26.1±2.0 grams at day 18; in the microcystin LR 
cohort treated daily the weight was 22.8±2.7 grams on day 0 
and 19.0±1.2 grams on day 18; and in the cohort treated every 
other day, the weights were 21.6±0.8 grams on day 0 and 
22.3±2.4 grams on day 18. The average tumor volume of the 
cohort treated every other day was 49% of control on day 18. 
Discussion 
The observation that microcystin LR and its analogs show 
potent growth inhibitory and cytoxicity activity in OATPl B l-
and OATP1B3-transfected cells in comparison to control 
18 
cells indicates both that the expression of these genes can 
impart selective sensitivity of cancer cells to cytotoxic sub-
strates, and that phosphatase inhibition may be a valid target 
for anticancer drug development. Furthermore, the lack of 
activity ofmicrocystin LR in the control HeLa cells demon-
strates that the stumbling block for developing microcystins 
as anticancer agents may be that these phosphatase inhibitors 
have difficulty gaining intracellular access in standard in vitro 
cytotoxicity models. This potential difficulty is supported by 
10 both our observations and those of others, that even hepatic-
derived cell lines do not reflect the level of transporter gene 
expression observed in the tissue and tumors of origin. In the 
case ofOATPlBl we found no detectable expression in any 
of the HCC or immortalized hepatocyte cell lines. In the case 
15 of OATP1B3, the level of mRNA expression in HCC and 
hepatocyte cell lines was at the limit of detection, and orders 
of magnitude lower than the expression levels seen in normal 
adult liver. In particular, the widely used Hep3B cell line does 
not express OATPlBl and the level ofOATP1B3 is orders of 
20 magnitude lower than the levels measured in normal liver. 
Also, another widely used model of hepatocellular carci-
noma, the HepG2 cell line, also does not express either trans-
porter (7). Similarly, the level of RNA expression in lung 
cancer cell lines is also low, even though direct measurement 
25 of RNA levels in lung tumor tissue showed increased expres-
sion relative to normal lung tissue, with the increased expres-
sion in the tumor samples being comparable to that of a 
normal liver reference. In the case of both transporters, the 
constitutive levels in all of the hepatic cell lines was at the 
30 level of the untransfected HeLa cells, whereas the transfected 
He La cells had mRNA levels similar to the levels measured in 
normal liver. We have seen a similar down regulation in cell 
lines versus tumors in the case of another membrane trans-
porter, OCT6 (19). Supporting our observations, the loss of 
35 microcystin sensitivity in freshly isolated trout and murine 
hepatocytes was observed to coincide with the rapid loss of 
OATP transporter gene expression when the hepatocytes are 
maintained in cell culture (20). Thus, down-regulation of 
membrane transport that occurs in adaptation to in vitro 
40 growth conditions has the potential to limit the interpretation 
of cell culture-based screening systems for polar cytotoxins 
that depend on specific mechanisms of drug uptake. 
Since transporter gene expression in tumors caunot be 
extrapolated from cell lines, direct measurement of tumor 
45 gene expression is required. However, studies quantifying 
mRNA levels in tumors also have limitations in interpreta-
tion. It is important to acknowledge that, while the data dem-
onstrate increased expression of OATP1B3 mRNA in lung 
tumors, these data must be interpreted with caution, as the 
50 mRNA levels do not necessarily reflect either protein expres-
sion or function. The actual sensitivity ofNSCLC tumors to 
microcystin analogs, and of microcystin uptake in NSCLC 
tumors relative to hepatocytes, are important questions to be 
explored with xenograft models (see, e.g., Examples 6 and 7 
55 herein). 
The microcystin concentrations that produced cytotoxicity 
in the transfected HeLa cells in our study, in the sub-nanolar 
range for microcystin LF and microcystin LW, appear to be 
significantly less than the doses required for hepatic toxicity. 
60 In mice given a sub-lethal dose ofmicrocystin LR (35 flg/kg), 
the peak plasma concentration achieved was 428 nM (21), 
compared to the IC50s of 5 nM and 39 nM for microcystin LR 
in OATPlBl and OATP1B3-transfected HeLa cells, respec-
tively (Table 2). Also, microcystin rapidly accumulate in the 
65 liver, with 70% of the total dose accumulating in the liver by 
30 min after the injection (21). We have demonstrated that the 
cytotoxic activity of microcystin LR is rapid, and although 
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maximal activity was not seen until 6 hours, a 1 hour exposure 
demonstrated significant levels of activity (FIG. 3E). 
20 
cytes to microcystic cyanobacteria extracts. Conversely, 
buthionine sulfoximine (BSO), an agent that decreases intra-
cellular glutathione, increased the sensitivity of the cultured 
hepatocytes to the cyanobacteria extract (32). These studies 
suggest that glutathione may play a role in the in vivo hepatic 
detoxification of microcystins at high concentrations. In our 
HeLa cell model, neither NAC nor BSO affected microcystin 
toxicity (data not shown). 
Our data strongly suggest that microcystin cytotoxicity in 
He La cells is related to specific PP2A inhibition. We found no 
correlation between global phosphatase inhibition and cyto-
toxicity. The similar concentrations for PP2A enzyme inhi-
bition and growth inhibition, and the linear correlation 
between the growthiC50 and the enzyme IC50 formicrocystin 
analogs, both suggest that specific PP2A inhibition is related 
to the toxic effect. 
The high concentration of microcystin in the liver achieved 
with a sublethal dose (21) suggests that hepatocytes may 
differ from cancer cells in the mechanism of microcystin 
toxicity. First, hepatic lethality may be related to an intracel-
lular target other than PP2A. One such target may be aldehyde 
dehydrogenase 11, an enzyme involved in acetetaldehyde 
detoxification and prevention of free radical formation, which 
was recently identified as a microcystin target from a peptide 
fragment that physically associated with microcystin LR 
using phage display methodology (22). Another potential 
microcystin target is the ~ subunit of ATP-synthase, which 
was shown to be a microcystin-binding protein using an anti-
microcystin antibody affinity purification colunm (23). 
In conclusion, therapeutic microcystin analogs may have 
10 the potential to exploit both differences in the mechanisms of 
toxicity and the availability of detoxification mechanisms in 
tumors versus normal hepatic tissue. The restricted hepatic 
expressionofOATP1B1 and OATP1B3 would help to prevent 
15 
toxicities to non-malignant tissues other than liver, and the 
expression of these transporters in NSCLC and hepatocellu-
lar carcinoma suggests that these tumors could be targeted 
with transporter-specific cytotoxins. Microcystins, as stable 
cyclic peptides with two variable amino acid positions, are 
20 attractive candidates for combinatorial synthesis, and the 
variation in potency between the first 5 microcystin analogs 
tested suggests that other analogs may be even more potent. 
Second, reports of microcystin cytotoxicity in non malig-
nant cells, in which a significantly higher dose is required for 
toxicity, is seemingly related to formation of reactive oxygen 
species (24) and resultant DNA damage (25). In lymphocytes 
in vitro, the mechanism of microcystin toxicity was associ-
ated with free radical formation; in those studies cells were 
exposed to micromolar concentrations of microcystin LR (26, 
27), in comparison to the sub-nanomolar range in the trans-
fected HeLa cells. 
While the present invention has been described with refer-
ence to specific embodiments, this application is intended to 
25 cover those various changes and substitutions that may be 
made by those of ordinary skill in the art without departing 
from the spirit and scope of the appended claims. 
The publications discussed herein are provided solely for 
their disclosure prior to the filing date of the present applica-
30 tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica-
tion by virtue of prior invention. Further, the dates of publi-
cation provided may be different from the actual publication 
Third, phosphatase inhibition may have different effects in 
tumor cells versus normal cells. Although protein phos-
phatases have tumor suppressor properties, phosphatases 
have been also been reported to promote cell growth and 
survival (9, 10). The cytotoxic effect of phosphatase inhibi-
tion may depend upon the reliance of a particular cell on the 
activity of specific kinases, which are often abnormally regu-
lated in cancer. For example, the phosphatase inhibitor oka- 40 
daic acid has been shown to induce apoptosis in a variety of 
cell lines, with increased sensitivity reported in cells carrying 
mutated Ras (28). Okadaic acid also induced apoptosis in 
malignant glioma cells, in studies which suggested an integral 
role for ERK and JNK kinases in promoting cell death (29). 45 
Rapid apoptosis has also been seen in primary hepatocytes 
following microinjection with both microcystin LR and 
nodularin, characterised by cytoplasmic shrinkage, chroma-
35 
dates, which may need to be independently confirmed. 
tin condensation, membrane blebbing and procaspase 3 
cleavage (30). Similarly, we have identified rapid cell death 50 
(within 6 hours), although at a much lower concentration (1 0 
nM) than those used by Fladmark and colleagues (nodu-
larin>250 f.LM and microcystin LR>50 f.LM). 
Finally, in addition to potential differences in microcystin 
intracellular targets between hepatocytes and cancer cells, 55 
there are also numerous metabolic differences between the 
normal hepatocyte and the malignant cell, and these differ-
ences might be exploited to create a therapeutic window for 
microcystin toxins. Microcystin and the related toxic cyclic 
peptide nodularin appear to stimulate glutathione-dependent 60 
detoxification pathways in hepatocytes. Exposure of rat hepa-
tocytes to sub-lethal concentrations of microcystin LR results 
in an acute increase in intracellular glutathione and an 
increase in the formation of reactive oxygen species (31 ). 
Significantly, addition ofN-acetylcysteine (NAC) to the cui- 65 
ture medium, an agent that increases intracellular glutathione 
concentrations, decreased sensitivity of cultured rat hepato-
All publications cited herein are hereby incorporated by 
reference in their entirety. 
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What is claimed is: 
1. A method of treating cancer, said method comprising 
administering to a mmalian subject in need thereof a phar-
maceutically effective amount of a microcystin which is not 
microcystin LR, wherein the cancer comprises cancer cells 
that express at least one ofOATP1B1 and OATP1B3 and the 
microcystin has improved cytotoxicity for the cells express-
ing at least one of OATP1B1 and OATP1B3 as compared to 
microcystin LR, wherein the cancer is selected from the 
group consisting of gastrointestinal cancer, lung cancer, gas-
tric cancer, colon cancer, pancreatic cancer, gall bladder can-
cer, breast cancer and glioblastoma; wherein said microcystin 
has the following formula: 
cyclo (D-Ala-X-erythro-~-methyl-D-iso-Asp-Y-adda-D­
iso-Glu-N-methyldehydro-Ala) wherein X is leucine 
andY is phenylalanine (MCLF) or tryptophan (MCLW). 
20. Boaru D A, Dragos N, Schirmer K. Microcystin-LR 
induced cellular effects in mammalian and fish primary 
hepatocyte cultures and cell lines: a comparative study. 
Toxicology 2006; 218:134-48. 
2. The method of claim 1, wherein said microcystins are 
45 substrates of at least one ofOATP1B1 and OATP1B3. 
21. Robinson N A, Pace J G, Matson C F, Miura G A, 
Lawrence W B. Tissue distribution, excretion and hepatic 
biotransformation of microcystin-LR in mice. J Pharmacal 
Exp Ther 1991; 256:176-82. 
22. Chen T, Cui J, Liang Y, eta!. Identification of human liver 50 
mitochondrial aldehyde dehydrogenase as a potential tar-
get for microcystin-LR. Toxicology 2006; 220:71-80. 
23. Mikhailov A, Harmala-Brasken AS, Hellman J, Meri-
luoto J, Eriksson J E. Identification of ATP-synthase as a 
novel intracellular target for microcystin-LR. Chern Bioi 55 
Interact 2003; 142:223-37. 
24. Ding W X, Nam Ong C. Role of oxidative stress and 
mitochondrial changes in cyanobacteria-induced apopto-
3. The method of claim 2, wherein said microcystins are 
substrates of both OATP1B1 and OATP1B3. 
4. The method of claim 2, wherein said microcystins are 
substrates ofOATP1B3 and not OATP1Bl. 
5. The method of claim 2, wherein said microcystins are 
substrates ofOATP1B1 and not OATP1B3. 
6. The method of claim 1, wherein said microcystin has at 
least one of improved cytotoxic potency and improved cyto-
toxic selectivity as compared to microcystin LR. 
7. The method of claim 1, wherein said microcystin is 
naturally-occurring. 
8. The method of claim 1, wherein said microcystin is 
synthetic. 
sis and hepatotoxicity. FEMS Microbial Lett 2003; 220: 
1-7. 
9. The method of claim 1, wherein said cancer comprises 
60 cells that express both OATP1B1 and OATP1B3. 
25. Ding W X, Sherr H M, Zhu H G, Lee B L, Ong C N. 
Genotoxicity of microcystic cyanobacteria extract of a 
water source in China. Mutat Res 1999; 442:69-77. 
26. LaukoffA, Carmichael WW, GrasmanKA, YuanM. The 
uptake kinetics and immunotoxic effects of microcystin- 65 
LR in human and chicken peripheral blood lymphocytes in 
vitro. Toxicology 2004; 204:23-40. 
10. The method of claim 1, wherein said cancer comprises 
cells that express OATP1B3 and not OATP1Bl. 
11. The method of claim 1, wherein said cancer comprises 
cells that express OATP1B1 and not OATP1B3. 
12. The method of claim 1, wherein said microcystin is 
administered at a dose that does not result in hepatic cytotox-
icity. 
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13. The method of claim 1, wherein said microcystin is 
administered as a pharmaceutical composition comprising 
one or more of a pharmaceutically acceptable diluent, carrier, 
and excipient. 
14. The method of claim 1, wherein said microcystin is 5 
administered in combination with other cancer modalities. 
15. The method of claim 14, wherein said other cancer 
modalities are selected from the group consisting of: chemo-
therapy, surgery, radiotherapy, hyperthermia, immuno-
therapy, hormone therapy, biologic therapy, and drugs to arne- 10 
liorate the adverse side effects of said cancer modalities. 
16. The method of claim 1, wherein said cancer is non-
small cell lung cancer, and said microcystin is selected from 
the group consisting of: cyclo (D-Ala-Leu-erythro-~-methyl-
D-iso-Asp-Phe-Adda-D-iso-Glu-N-methyldehydro-Ala) 15 
and cyclo (D-Ala-Leu-erythro-~-methyl-D-iso-Asp-Try­
Adda-D-iso-Glu-N -methy ldehydro-Ala). 
17. The method of claim 1, wherein said cancer is hepato-
cellular carcinoma, and said microcystin is selected from the 
group consisting of: cyclo (D-Ala-Leu-erythro-~-methyl-D- 20 
iso-Asp-Phe-Adda-D-iso-Glu-N-methyldehydro-Ala) and 
cyclo (D-Ala-Leu-erythro-~-methyl-D-iso-Asp-Try-Adda-
D-iso-Glu-N-methyldehydro-Ala). 
18. The method of claim 1, wherein said cancer is colon 
cancer. 25 
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